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Previously, we showed that serum soluble interleukin-2 receptor (sIL-2R) levels, a marker for T-cell activation, were higher in
complex regional pain syndrome (CRPS) patients than in healthy controls, suggesting pathogenic T-cell activation in CRPS.
Additionally, sIL-2R levels discriminated well between CRPS and healthy controls with a high sensitivity (90%) and specificity
(89.5%), suggesting a possible role for sIL-2R in the diagnosis of CRPS. In order to further validate this marker in the diagnostic
workup of CRPS, we conducted this prospective cohort study in which we determined sIL-2R levels in patients that were
referred to our tertiary referral center with a suspicion of CRPS in a limb, and subsequently compared sIL-2R levels between the
patients that were diagnosed with CRPS (CRPS group) and those who were not (no CRPS group). A group of anonymous blood
bank donors were used as a healthy control group. Furthermore, we explored the relationship between sIL-2R and CRPS disease
severity using the CRPS severity score. Median sIL-2R levels of both the CRPS group (2809.0 pg/ml; Q3-Q1: 3913.0-1589.0) and
no CRPS group (3654.0 pg/ml; Q3-Q1: 4429.0-2095.5) were significantly higher than that of the control group (1515.0 pg/ml;
Q3-Q1: 1880.0-1150.0): CRPS vs. controls, p < :001; no CRPS vs. controls, p < 0:001. Serum sIL-2R levels did not differ
significantly between the CRPS and no CRPS group. A statistically significant negative correlation was observed between sIL-2R
levels and the CRPS severity score (rs = −0:468, p = 0:024). Our results confirm our previous findings of higher sIL-2R levels in
CRPS patients than in healthy controls. We further showed that serum sIL-2R cannot differentiate between CRPS and other
pain conditions of a limb in a tertiary referral setting. Interestingly, a negative correlation was found between sIL-2R and CRPS
disease severity; this finding warrants further research into the relationship between sIL-2R and CRPS disease severity.
1. Introduction
Complex regional pain syndrome (CRPS) is characterized by
continuous pain which is accompanied by various sensory,
motor, vasomotor, sudomotor, and trophic disturbances
[1]. The onset of CRPS is preceded by damage to the tissues
of a limb, for example, due to fracture or surgery [2]. If CRPS
is left untreated, it can have incapacitating consequences not
only on the function of the affected limb, but also on the
social life of patients [3]. However, appropriate treatment is
often initiated too late due to a delay in diagnosis [4].
This diagnostic delay is mostly due to two reasons. First,
the diagnosis of CRPS is still based on a set of relatively sub-
jective criteria: the New International Association for the
Study of Pain clinical diagnostic criteria for CRPS [1]. Thus,
the (early) diagnosis of CRPS cannot yet be established by
objective diagnostic testing. Second, the pathophysiology of
CRPS is complex and still incompletely understood; this lack
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of understanding creates skepticism among physicians on
whether this disease exists [5, 6] and further leads to a general
lack of awareness on the symptoms and signs of this disease.
Although the pathophysiology of CRPS is still incom-
pletely understood, it has been established that it comprises
of multiple disease mechanisms [7]. Inflammation is recog-
nized as one of the pathophysiological mechanisms contrib-
uting to CRPS. This inflammation may, in part, be related
to dysregulation of the immune system associated with
altered T-cell activity [8–10]. Our group previously assessed
T-cell activity in CRPS patients by measuring serum levels
of the soluble interleukin-2 receptor (sIL-2R): a marker for
T-cell activation [8, 11, 12]. We found significantly higher
serum sIL-2R levels in the CRPS group than in healthy con-
trols, supporting the notion of pathological T-cell activation
in CRPS [8]. Moreover, serum sIL-2R level discriminated
well between CRPS patients and healthy controls, with a high
sensitivity (90%) and specificity (89.5%) [8].
This last finding is especially noteworthy as it indicates
that serum sIL-2R may represent a biomarker to facilitate
the diagnosis of CRPS. Elevated serum sIL-2R levels are,
however, not disease specific as this is found in many differ-
ent disease entities, including immune and rheumatic dis-
eases, as well as malignancies [13]. Yet, the potential
diagnostic value of serum sIL-2R was recently demonstrated
in a retrospective cohort study in patients suspected of sar-
coidosis [14]. On the basis of an established cut-off value,
the sensitivity and specificity of serum sIL-2R for the detec-
tion of sarcoidosis were 88% and 85%, by far superior to
angiotensin-converting enzyme (ACE; the classical bio-
marker for sarcoidosis with a sensitivity of 62% and specific-
ity of 88%) [14]. Therefore, we consider it of interest to
further explore the potential application of serum sIL-2R
measurement in establishing the diagnosis of CRPS. At this
moment, biomarkers validated for use in the diagnosis of
CRPS are not available. However, identification of potential
diagnostic biomarkers could greatly aid in preventing a
delayed diagnosis and starting appropriate and timely
therapy in CRPS.
Previously, we determined serum sIL-2R levels only in
CRPS patients and healthy controls and consequently, we
could not draw conclusions on the role of serum sIL-2R in
the diagnostic workup of CRPS [8]. Therefore, in this current
study, we examined whether serum sIL-2R can be used to
differentiate CRPS from other pain conditions of a limb in
patients referred to a tertiary referral center due to a
suspicion of CRPS.
2. Materials and Methods
2.1. Ethical Approval. This study was conducted according
to the principles of the Declaration of Helsinki and in
accordance with the Medical Research Involving Human
Subjects Act (WMO). The study was approved by the
Medical Ethics Committee of Erasmus MC University
Medical Center Rotterdam (MEC-2017-495). The trial
was registered in the Netherlands Trial Registry
(NTR7465).
2.2. Study Design, Recruitment, and Study Population. This
prospective cohort study was conducted at the Center for
Pain Medicine (CPM) at Erasmus MC University Medical
Center which is a teaching hospital located in Rotterdam,
the Netherlands. The CPM is a tertiary referral center with
CRPS being one of the fields of expertise. Patients are referred
to our center by general physicians or other specialists such
as orthopedic surgeons.
All patients referred to our center with a suspicion of
CRPS in one limb were invited to participate in this study.
Two weeks before their first outpatient clinic appointment,
patients were approached by a study physician with both ver-
bal and written information on the study. The patients could
decide on the day of their appointment whether they wanted
to participate in the study. Patients were informed that the
results of this study would not influence the diagnosis or
treatment of their disease. After obtaining informed consent,
the inclusion and exclusion criteria described in Table 1 were
applied. Patients were included consecutively until the
required sample size was reached. The inclusion period
started in March 2018 and ended in August 2019.
Serum sIL-2R levels available from 101 anonymous
healthy blood bank donors served as a reference for serum
sIL-2R levels in the healthy population. Thus, the study
population consisted of 3 groups: patients finally diag-
nosed with CRPS (CRPS group), patients finally diagnosed
with a condition other than CRPS (no CRPS group), and
healthy controls.
2.3. Study Measurements and Data Collection. The following
data were collected during the outpatient clinic appointment:
age; duration of disease (i.e., duration of symptoms and
signs); precipitating injury (i.e., initiating factor of symptoms
and signs); affected limb; medication; intensity of pain at the
moment of the visit and in the past 24 hours using an 11-
point numeric rating scale (NRS); and symptoms and signs
recorded using the CRPS severity score-Database Form
developed by Harden et al. along with the resulting CRPS
severity score (CSS) [15] (Table 2). Permission was received
from N. Harden for use of the CRPS severity score-
Database Form [15]. The study physicians followed the
instructions of the CRPS severity score-Database Form to
register symptoms and signs during physical examination.
At the end of the appointment, one 5-milliliter tube of
venous blood was drawn for sIL-2R analysis.
2.4. Diagnosis of CRPS Group and No CRPS Group. CRPS was
diagnosed using the widely accepted New International
Association for the Study of Pain clinical diagnostic criteria
for CRPS [1]. All other diagnoses were established using
appropriate and up-to-date guidelines, and when needed,
patients were referred to the appropriate specialty. The diag-
noses of patients in the no CRPS group were divided into the
following categories: neuropathic pain syndromes, myofas-
cial pain syndromes, vascular diseases, inflammatory condi-
tions, and psychiatric problems/disorders. These categories
were derived from the differential diagnosis of CRPS as
described in the article by van Eijs et al. [16].
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2.5. sIL-2R Analysis. Venous blood samples were centrifuged
at 3000 rpm after collection, and serum was subsequently
isolated. Soluble IL-2R levels were measured using an
enzyme-linked immunosorbent assay (Human sCD25/sIL-
2R ELISA kit, Besancon, Cedex, France) according to the
manufacturer’s instructions at the diagnostic Laboratory
Medical Immunology facility of Erasmus MC University
Medical Center Rotterdam. The measurements were
conducted under strict quality procedures (ISO15189).
2.6. Sample Size Calculation. Based on the results of our pre-
vious study [8], we chose a statistically detectable and clini-
cally relevant effect size (d) of 1.0 on serum sIL-2R level
using an independent t-test. The power of the study (1-β)
was set at 0.8, the allocation ratio at 0.25, and the two-sided
level of significance (α) at 0.05. The required sample size
computed by this method was 52.
2.7. Statistical Analysis. Descriptive statistics were used to
calculate the frequencies of categorical variables and to calcu-
late measures of central tendency and variability of continu-
ous variables. The Shapiro-Wilk test was used to analyze
whether continuous variables were normally distributed.
Variables with a skewed distribution are reported in medians
and interquartile ranges (Q3-Q1), otherwise means and stan-
dard deviations are used. The primary outcome parameter
was the serum sIL-2R level in the CRPS group, no CRPS
group, and healthy control group.
Depending on the shape of distribution, continuous var-
iables were compared between two groups using either a two-
sided independent t-test or a two-sided Mann-Whitney U
test. Comparison of continuous variables between more than
two groups was conducted using either an ANOVA or a
Kruskal-Wallis test, dependent on the shape of the distribu-
tion of the variable. Categorical variables were compared
using the Fisher’s exact test.
A possible association in the CRPS group between sIL-2R
levels and age, sIL-2R levels and duration of disease, and sIL-
2R levels and the CRPS severity score was explored using
either a Pearson’s correlation or a Spearman’s rank correla-
tion, dependent on the shape of the distribution of these
variables. A possible association in the CRPS group between
sIL-2R levels and gender was explored using a point-biserial
correlation.
Where possible, data are presented in tables and graphs,
such as box-and-whisper plots and scatterplots. For box-
and-whisper plots that are created in SPSS, the box repre-
sents the interquartile range and the whiskers extend to the
highest and lowest value in the data range which are no
greater than 1.5 times the interquartile range. Circles in the
box-and-whisker plots indicate outliers that are between 1.5
and 3 times the interquartile range. Analyses were performed
using IBM SPSS Statistics 21. The alpha level for statistical
significance was set at 0.05.
3. Results
Figure 1 depicts the recruitment and inclusion of our study
population. A total of 86 patients were approached to partic-
ipate in this study. Twenty-nine patients did not participate
in the study: one patient canceled the outpatient clinic
appointment; one patient did not show up at the appoint-
ment; two patients had an incorrect referral; five patients
declared, of their own accord, during the phone call that they
have an autoimmune or autoinflammatory disorder with or
without use of immunomodulating medication; six patients
were unwilling to participate in research; fourteen patients
were unreachable when called. Fifty-seven patients signed
the informed consent form. Five patients were excluded after
signing the form: two patients were excluded due to use of
prednisolone; one patient did not have time to complete the
outpatient visit; one patient backed out without further
explanation; one patient was excluded because of a history
of active psoriasis. This resulted in the required sample size
of 52 patients for analysis.
Of the 52 patients, 23 patients (44%) were diagnosed with
CRPS and 29 patients (56%) were diagnosed with other con-
ditions (no CRPS group). Of the no CRPS group, 7 patients
(24.1%) were diagnosed with neuropathic pain syndromes,
17 (58.6%) with myofascial pain syndromes, 2 patients
Table 1: Inclusion and exclusion criteria applied in this study.
Patients had to meet both the inclusion criteria and were excluded
if they met any of the exclusion criteria.
Inclusion criteria Exclusion criteria
Age ≥ 18 years History of an autoinflammatory or
autoimmune disease
Only one limb is
affected
Current or past (within the last six months)
treatment with immunomodulating
medication such as steroids or TNF-α
inhibitors
Ill in the past two weeks or at the time of visit
Potential pregnancy or confirmed pregnancy
Table 2: Symptoms and signs assessed using the CRPS severity
score-Database Form by Harden et al. [15].
Symptoms∗1 Signs∗2
Continuing, disproportionate
pain
Hyperalgesia to single pinprick
Allodynia or hyperalgesia Allodynia
Temperature asymmetry
Temperature asymmetry by
palpation
Color asymmetry Color asymmetry
Sweating asymmetry Sweating asymmetry
Edema Asymmetric edema
Dystrophic changes Dystrophic changes
Motor abnormalities∗3 Motor abnormalities∗4
∗1Symptoms as reported by the patient. All symptoms are categorical
variables and are registered as absent or present. ∗2Signs as observed
during physical examination by the physician. All signs are categorical
variables and are registered as absent or present. ∗3Motor abnormalities as
reported by the patient: weakness, tremor, dystonia, decreased range of
motion, and myoclonus. ∗4Motor abnormalities as observed by the
examiner: tremor/myoclonus, dystonia, decreased active range of motion,
and weakness.
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(6.9%) with inflammatory conditions, and 3 patients (10.3%)
had an unclear or unknown diagnosis. No diagnoses were
made that could be categorized as vascular diseases or psychi-
atric problems/disorders. Full details of the no CRPS group,
including diagnoses that were made per category, can be
found in Table 3.
Patient characteristics such as age, gender, affected limb,
precipitating injury, and duration of disease were comparable
between both the CRPS group and the no CRPS group
(Table 4). Use of medication was also comparable between
both groups (Table 5). Median pain scores at the time of visit
and 24 hours before the visit were also comparable between
both groups (Table 6).
Table 6 shows the proportion of symptoms and signs in
each group recorded according to the CRPS severity score-
Database Form [15]. The prevalence of the following symp-
toms (i.e., subjective symptoms reported by patients) was sig-
nificantly higher in the CRPS group than in the no CRPS
group: continuing pain, color asymmetry, and decreased
active range of motion of the affected limb. The prevalence
of the following signs (i.e., objective signs observed by the
physician) was significantly higher in the CRPS group than
in the no CRPS group: hyperalgesia to pinprick; allodynia
and its corresponding subcategories; temperature asymme-
try, with all affected CRPS patients having a cooler affected
limb; color asymmetry and its corresponding subcategory
“red”; sweating asymmetry, with all affected CRPS patients
experiencing increased sweating on the affected side; and
asymmetric edema. The mean CRPS severity score was sig-
nificantly higher in the CRPS group than in the no CRPS
group (CRPS 11.4 (sd = 2:2) versus no CRPS 8.1 (sd = 1:9),
p < 0:001).
The median sIL-2R levels of both the CRPS group
(2809.0 pg/ml; Q3-Q1: 3913.0-1589.0) and no CRPS group
(3654.0 pg/ml; Q3-Q1: 4429.0-2095.5) were significantly
higher than the median sIL-2R level of the control group
(1515.0 pg/ml; Q3-Q1: 1880.0-1150.0): CRPS group vs. con-
trol group, p < :001 and no CRPS group vs. control group, p
Approached to participate (n=86)
Enrollment
Assessed for eligibility (n=57)
Included for analysis (n=52)
Analysis
No-CRPS (n=29) CRPS (n=23)
Excluded (n=29)
Excluded (n=5)
󳴥 Unreachable when called (n=14)
󳴥 Declined to participate (n=6)
󳴥 Incorrect referral (n=2)
󳴥 Canceled appointment (n=1)
󳴥 Not meeting inclusion criteria (n=3)
󳴥 Declined to participate (n=1)
󳴥 Could not complete outpatient visit (n=1)
󳴥 Did not show up to outpatient visit (n=1)
󳴥 Patient declared they had an
autoinflammatory or
autoimmune disorder with or
without use of
immunodmodulating medication
(n=5)
Figure 1: Flow diagram depicting the recruitment and inclusion of the study population.
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Table 3: Diagnosis and median sIL-2R level per group.
Diagnosis Total patients per group Median sIL-2R pg/ml (Q3-Q1)
Healthy controls 101 1515.0 (1880.0-1150.0)
CRPS group 23 2809.0 (3913.0-1589.0)
No CRPS group 29 3654.0 (4429.0-2095.5)
Neuropathic pain syndromes∗1 (n, % no CRPS group) 7 (24.1) 4170.0 (5203.0-2050.0)
Myofascial pain syndromes∗2 (n, % no CRPS group) 17 (58.6) 3529.0 (4253.5-2150.5)
Inflammation∗3 (n, % no CRPS group) 2 (6.9) N/A
Unknown∗4 (n, % no CRPS group) 3 (10.3) N/A
∗1Neuropathic pain syndromes: peripheral neuropathy (n = 5); cervical dermatomal pain (n = 1); radicular pain (n = 1). ∗2Myofascial pain syndromes:
postfracture pain and osteoarthritis (n = 1); osteoarthritis (n = 1); disuse (n = 1); myalgia (n = 1); disability and impairment of hand related to fracture as
diagnosed by plastic surgeon (n = 2); shin splints (n = 1); subacromial pain syndrome (n = 1); unspecified pain of the shin (n = 1); suspected patellofemoral
pain syndrome (n = 1); suspected clenched fist syndrome (n = 1); pain related to healing process after trauma (n = 4); postsurgical pain (n = 2). ∗
3Inflammation: osteomyelitis (n = 1); arthritis of the wrist (n = 1). Median sIL-2R levels were not calculated due to the size of the group. ∗4Median sIL-2R
levels were not calculated due to the size of the group.
Table 4: Patient demographics and general characteristics of the no CRPS and CRPS group.
Demographics and characteristics No CRPS (n = 29) CRPS (n = 23) Significance
Age in years (median, (Q3-Q1)) 43.0 (55.5-27.5) 37.0 (55.0-28.0) NS
Duration of disease in months (median, (Q3-Q1)) 20.0 (36.0-8.5) 26.0 (81.0-14.0) NS
Gender NS
Male (n, %) 10 (34.5) 4 (17.4)
Female (n, %) 19 (65.5) 19 (82.6)
Affected limb NS
Right upper limb (n, %) 6 (20.7) 5 (21.7)
Left upper limb (n, %) 5 (17.2) 4 (17.4)
Right lower limb (n, %) 6 (20.7) 4 (17.4)
Left lower limb (n, %) 12 (41.4) 10 (43.5)
Precipitating injury NS
Trauma 13 (44.8) 11 (47.8)
Operation 11 (37.9) 9 (39.1)
Spontaneous 5 (17.2) 0
Other 0 2 (8.7)
Unknown 0 1 (4.3)
Table 5: Medications being used at the time of visit at the outpatient clinic center.
Medication No CRPS (n = 29) CRPS (n = 23) Significance
Paracetamol (n, %) 10 (34.5) 9 (39.1) NS
NSAIDs∗1 (n, %) 10 (34.5) 5 (21.7) NS
Opioids (n, %) 5 (17.2) 8 (34.8) NS
Antidepressants (n, %) 3 (10.3) 6 (26.1) NS
Antiepileptics (n, %) 3 (10.3) 6 (26.1) NS
Calcium channel blockers (n, %) 1 (3.4) 2 (8.7) NS
Phosphodiesterase-5 inhibitor (n, %) 0 0 N/A
Vitamin C (n, %) 6 (20.7) 3 (13.0) NS
Fluimucil or N-acetyl cysteine (n, %) 0 1 (4.3) N/A
DMSO∗2 (n, %) 2 (6.9) 0 N/A
∗1NSAIDs: nonsteroidal anti-inflammatory drugs. ∗2DMSO: dimethylsulfoxide cream.
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Table 6: CRPS severity score-Database Form: presence of symptoms and signs of CRPS in each group.
Symptoms No CRPS (n = 29) CRPS (n = 23) Significance
NRS at time of visit (median, Q3-Q1) 7.0 (8.0-3.0) 7.0 (8.0-6.0) NS
NRS 24 hours before visit (median, Q3-Q1) 7.5 (8.0-6.3) 8.0 (8.0-7.0) NS
Continuing pain (n, %) 18 (62.1) 23 (100) p = 0:001
Allodynia and/or hyperalgesia 27 (93.1) 23 (100) NS
Allodynia 14 (48.3) 17 (73.9) NS
Hyperalgesia 24 (82.8) 23 (100) NS
Temperature asymmetry 27 (93.1) 20 (87.0) NS
Affected side warmer 11 (37.9) 7 (30.4) NS
Affected side colder 9 (31.0) 5 (21.7) NS
Affected side warm/cold 7 (24.1) 8 (34.8) NS
Color asymmetry 23 (79.3) 23 (100) p = 0:028
Red 14 (48.3) 13 (56.5) NS
Blue 5 (17.2) 8 (34.8) NS
Other color 12 (41.4) 14 (60.9) NS
Sweating asymmetry 12 (41.4) 14 (60.9) NS
Edema 24 (82.8) 21 (91.3) NS
Dystrophic changes 15 (51.7) 17 (73.9) NS
Nails 10 (34.5) 12 (52.2) NS
Hair 8 (27.6) 11 (47.8) NS
Skin 6 (20.7) 10 (43.5) NS
Motor abnormalities 29 (100) 23 (100) N/A
Weakness 25 (86.2) 22 (95.7) NS
Tremor 15 (51.7) 13 (56.5) NS
Dystonia 13 (44.8) 10 (43.5) NS
Decreased AROM 20 (69.0) 22 (95.7) p = 0:030
Myoclonus 4 (13.8) 9 (39.1) NS
Signs No CRPS (n = 29) CRPS (n = 23) Significance
Hyperalgesia to pinprick 11 (37.9) 17 (73.9) p = 0:013
Allodynia 18 (62.1) 22 (95.7) p = 0:007
Light touch 6 (20.7) 19 (82.6) p < 0:001
Deep joint pressure 9 (31.0) 18 (78.3) p = 0:002
Vibration 8 (27.6) 14 (60.9) p = 0:021
Cold 2 (6.9) 11 (47.8) p = 0:002
Heat 3 (10.3) 11 (47.8) p = 0:004
Temperature asymmetry on palpation 2 (6.9) 8 (34.8) p = 0:015
Affected side cooler 1 (3.4) 8 (34.8) p = 0:007
Affected side warmer 1 (3.4) 0 NS
Color asymmetry 4 (13.8) 12 (52.2) p = 0:006
Red 3 (10.3) 9 (39.1) p = 0:021
Blue or pale 3 (10.3) 4 (17.4) NS
Mottled 0 4 (17.4) N/A
Scar 0 0 N/A
Sweating asymmetry 1 (3.4) 6 (26.1) p = 0:035
Increased on affected side 1 (3.4) 6 (26.1) p = 0:035
Decreased on affected side 0 0 N/A
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< 0:001. Serum sIL-2R levels did not differ significantly
between the CRPS group and no CRPS group (Figure 2 and
Table 3).
Of the no CRPS group, both the neuropathic pain syn-
drome group (4170.0 pg/ml; Q3-Q1: 5203.0-2050.0) and
myofascial pain syndrome group (3529.0 pg/ml; Q3-Q1:
4253.5-2150.5) had median sIL-2R levels that were signifi-
cantly higher than the median sIL-2R level of healthy con-
trols (1515.0 pg/ml; Q3-Q1: 1880.0-1150.0): neuropathic
pain syndrome group versus control group, p < 0:001 and
myofascial pain syndrome group versus control group, p <
0:001. There was no significant difference in the distribution
of sIL-2R levels between the neuropathic pain syndrome
group, myofascial pain syndrome group, and the CRPS group
(Figure 3 and Table 3).
Within the CRPS group, a statistically significant nega-
tive correlation existed between serum sIL-2R levels and the
CRPS severity score (rs = −0:468, p = 0:024, Figure 4). No
association was found between serum sIL-2R level and age,
gender, and disease duration in the CRPS group.
4. Discussion
So far, objective diagnostic tests to diagnose CRPS are not
available. This lack of objective tests hampers early diagnosis
and timely initiation of appropriate therapies [17]. Based on
the findings from our previous study in which sIL-2R levels
were found to be significantly higher in CRPS patients than
in healthy controls [8], we conducted this current study in
which we investigated whether serum sIL-2R could be used
to help establish the diagnosis CRPS in patients who were
referred to a tertiary referral center with pain in a limb that
was suspected to be caused by CRPS. To our knowledge, this
is the first study assessing the differentiating capacity of
serum sIL-2R in CRPS. Our results indicate that serum sIL-
2R is not useful for differentiating CRPS from other pain
conditions of a limb in patients referred with a suspicion of
CRPS to a tertiary referral center.
One of the main explanations why serum sIL-2R may not
be useful in differentiating CRPS from other pain conditions
of a limb may be that altered T-cell activity occurs in various
diseases that are part of the initial differential diagnosis of
CRPS. For example, there are diseases in the differential diag-
nosis of CRPS that have been proven to involve T-cell activa-
tion and have been shown to have elevated sIL-2R levels,
such as rheumatoid arthritis [13, 18]. Recently, carpal tunnel
syndrome (CTS)—which also needs to be considered in the
differential diagnosis of CRPS of the upper limb—was shown
to be associated with elevated percentages of central and
effector memory CD4+ T-cells which is suggestive of changes
in memory T-cell homeostasis in CTS [19]. Therefore, we
consider it likely that serum sIL-2R levels may be elevated
in CTS patients as well, although data on this is lacking so
far. There is also evidence that altered T-cell activity may play
a role in (the development of) neuropathic pain [20, 21]. It is
thus plausible that there is altered T-cell activity in the vari-
ous diseases that make up the differential diagnosis of CRPS,
thereby diminishing any differentiating power serum sIL-2R
may have in the diagnosis of CRPS. Moreover, as stated in the
introduction, elevated serum sIL-2R levels are not disease
specific as elevated levels of sIL-2R can be found in many
different diseases [12, 13].
In this study, we have confirmed our previous finding of
elevated serum sIL-2R levels in CRPS, indicating that T-cell
activation is involved in the pathogenesis of CRPS [8–10].
It was further observed that the group of neuropathic pain
syndromes was also associated with elevated serum sIL-2R
levels, indicating that T-cell activation is likely to be involved
in these pain syndromes. In line with this, recent observa-
tions in animal models support an important role for T-
cells in (the development of) neuropathic pain [20, 21]. We
also found significantly higher sIL-2R levels in the myofascial
pain syndrome group than in the group of healthy controls.
This may be related to the various diagnoses we categorized
into this group. For reasons of simplicity, we categorized
diseases as myofascial pain syndromes if they were not
Table 6: Continued.
Symptoms No CRPS (n = 29) CRPS (n = 23) Significance
Asymmetric edema 1 (3.4) 6 (26.1) p = 0:035
Dystrophic changes 4 (13.8) 7 (30.4) NS
Nails 1 (3.4) 5 (21.7) NS
Hair 3 (10.3) 2 (8.7) NS
Skin 1 (3.4) 4 (17.4) NS
Motor abnormalities affected side 20 (69.0) 21 (91.3) NS
Tremor or myoclonus 2 (6.9) 6 (26.1) NS
Dystonia 2 (6.9) 7 (30.4) NS
Decreased AROM 16 (55.2) 17 (73.9) NS
Weakness 1/5∗1 0 3 (13.0) N/A
Weakness 2/5∗2 0 5 (21.7) N/A
Weakness 3/5∗3 4 (13.8) 5 (21.7) NS
Weakness 4/5∗4 12 (41.4) 7 (30.4) NS
CRPS severity score (mean, sd) 8.1 (1.9) 11.4 (2.2) p<0.001
∗1Weakness 1/5: flicker of movement. ∗2Weakness 2/5: movement with gravity. ∗3Weakness 3/5: movement against gravity. ∗4Weakness 4/5: weak.
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considered neuropathic or “classically inflammatory” by
nature. However, it is not unthinkable that certain diseases
we classified in this group, such as osteoarthritis, could reveal
increased sIL-2R levels (Table 3) [22]. Nevertheless, studies
in larger cohorts should separately explore the contribution
of T-cells to the various diseases categorized into the group
of myofascial pain syndromes.
Interestingly, we further found a statistically significant
negative correlation between sIL-2R levels and the CRPS
severity score in our CRPS patients. We propose three expla-
nations for this negative correlation in our cohort of CRPS
patients. First, it is possible that serum sIL-2R level reflects
T-cell-driven inflammatory disease activity (the intensity of
the inflammatory process) rather than disease severity (the
impact of the disease activity on the limb) in CRPS. Such
would indicate that serum sIL-2R level measured in CRPS
may be strongly related to the phase of disease. Patients in
the acute phase of CRPS often present with the warm subtype
of CRPS [2, 23]. As the disease progresses and becomes
chronic, most patients undergo a change from a warm
(acute) subtype to a cold (chronic) subtype [24]. It is thought
that this subtype transition is caused by a change in active
underlying pathophysiological mechanisms during the
course of this syndrome. For example, inflammatory mecha-
nisms seem to be most prominent in the warm (acute) CRPS
subtype and seem to diminish as the disease progresses [24].
However, (tissue) damage inflicted by the early inflammatory
phase may persist and even worsen because of other patho-
physiological mechanisms that gain the upper hand. Consid-
ering that all CRPS patients in this study had chronic CRPS,
it is possible that in this group of chronic CRPS patients, T-
cell-mediated inflammatory disease activity, and thus sIL-
2R level, has diminished over time while the damage caused
by this activity—the disease severity—remains extensive. It
would be interesting to test this hypothesis with serial
measurements of sIL-2R in a prospective cohort of acute
CRPS patients.
Second, this negative correlation may be explained by an
immunosuppressive biological function of sIL-2R. The sIL-
2R is the circulating form of the α-chain of the membrane-
bound high-affinity trimeric interleukin-2 (IL-2) receptor.
IL-2 is an important regulatory cytokine for the activation,
proliferation, differentiation, and survival of different T-cell
subsets [12, 25, 26]. It has been suggested that circulating
sIL-2R competes for available IL-2 and may limit activation
and proliferation of T-lymphocytes by sequestration of avail-
able IL-2 [12, 25, 27–31]. It has further been proposed that
sIL-2R presents IL-2 to CD4+ T-helper cells, thereby
inducing T-cell differentiation towards anti-inflammatory
T-regulatory cells (Tregs) instead of proinflammatory Th1
or Th17 cells [25, 32]. Considering that the discovered nega-
tive correlation suggests a higher sIL-2R is associated with
less disease severity, it can be hypothesized that sIL-2R may
have an immunosuppressive, and thus protective, biological
function in CRPS. This idea is partially supported by the
findings in the study by Heyn et al. in which the authors
found a significantly lower percentage of proinflammatory
Th17 cells, a lower Th17/Treg ratio, and a significantly higher
proportion of anti-inflammatory CD39+Tregs in a group of
CRPS patients, suggesting an anti-inflammatory T-cell shift
in CRPS [9].
Third, the negative correlation may reveal an inability of
our clinical observations to objectify a possible T-cell-
mediated inflammatory pathology and the related disease
activity and severity in CRPS. This inability of our clinical
observations to reflect an underlying pathology could explain
the discrepancy between biochemical changes and clinical
findings that are often found in CRPS.
Thus, although in our current study serum sIL-2R seems
to lack diagnostic value when it comes to differentiating
CRPS from other pain conditions of a limb with a similar
presentation, it seems that this marker may have a potential
role in the monitoring of disease activity and/or severity of
CRPS. This warrants future research in which the relation-
ship between serum sIL-2R levels and disease activity and
severity of CRPS are explored.
We made two interesting observations in this study: first,
our current study population had a relatively long disease
duration; second, at the time of measurement, patients who
suffered from temperature changes all had a cool limb. Our
Center for Pain Medicine is a tertiary referral center, and it
seems that the cases that are referred to us are usually the
cases that are refractory to therapy and can be considered
to have chronic (cold type) CRPS based on the disease dura-
tion. Thus, a limitation of our study is that there may be a
referral bias in the study population resulting in a patient
sample that may not be completely representative of the gen-
eral CRPS patient population. Therefore, it is not unlikely
that if this study were to be replicated in another setting such
as a secondary hospital where patients are seen at an earlier
stage and/or with a warm limb, it might return different
results. We therefore suggest that future research replicates
this study in a primary or secondary care setting. Further-
more, future research should also focus on measuring other
inflammatory markers in CRPS, for example, cytokines or
other soluble surface molecules secreted from activated
immune cells.
Another limitation of our study is that the current sample
size was calculated based on the effect size which was derived
from our first study in which we investigated whether there
was a difference in serum sIL-2R levels between CRPS
patients and healthy controls [8]. The observed effect size
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Figure 2: Boxplot of the median sIL-2R levels in the no CRPS group
(3654.0 pg/ml; Q3-Q1: 4429.0-2095.5), the CRPS group
(2809.0 pg/ml; Q3-Q1: 3913.0-1589.0), and the control group
(1515.0 pg/ml; Q3-Q1: 1880.0-1150.0): CRPS vs. controls, p < :001
and no CRPS vs. controls, p < 0:001.
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from this previous study was rather large and may have led to
an underestimation of the required sample size for the cur-
rent study. Therefore, this study may have been underpow-
ered for the primary outcome: the difference between sIL-
2R levels in the CRPS group and no CRPS group. Further-
more, we chose not to conduct corrections for multiple
testing with regard to the secondary outcomes as it may have
barred the discovery of potential associations that could be of
interest to explore in future research.
Despite the limitations mentioned above, we believe that
the greatest strength of our study is the selection of the study
population. All patients included in this study were suspected
of having CRPS. Therefore, our no CRPS group consisted of
various diseases that can display the same symptoms and
signs as CRPS in a limb. Thus, our study design closely
reflects clinical practice, especially in a tertiary care setting,
and could be used as a model for replication studies.
5. Conclusion
In summary, we conclude that serum sIL-2R cannot be used
in a tertiary referral setting to differentiate CRPS from other
pain conditions of a limb in patients referred with a suspicion
of CRPS. Our current findings confirm the findings from our
previous study in which serum sIL-2R levels are shown to be
higher in CRPS patients than in healthy controls, suggesting
a role for pathogenic T-cell activation in CRPS [8].
Although serum sIL-2R may not be useful in establishing
the diagnosis CRPS, future studies should focus on replicat-
ing this study in a primary and/or secondary care setting
and should further focus on exploring the relationship
between sIL-2R and (T-cell mediated) disease activity and
disease severity in CRPS. These explorations could reveal a
possible role for sIL-2R as a biomarker for disease activity
and/or severity in CRPS and could further reveal a possible
role for sIL-2R as a biomarker for selection of (anti-inflam-
matory) therapies in CRPS.
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